NZ563261A - Effectors of innate immunity - Google Patents

Effectors of innate immunity

Info

Publication number
NZ563261A
NZ563261A NZ563261A NZ56326102A NZ563261A NZ 563261 A NZ563261 A NZ 563261A NZ 563261 A NZ563261 A NZ 563261A NZ 56326102 A NZ56326102 A NZ 56326102A NZ 563261 A NZ563261 A NZ 563261A
Authority
NZ
New Zealand
Prior art keywords
seq
control
peptide
protein
cells
Prior art date
Application number
NZ563261A
Other languages
English (en)
Inventor
Robert E W Hancock
B Brett Finlay
Monisha Gough Scott
Dawn Bowdish
Carrie Melissa Rosenberger
Jon-Paul Steven Powers
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia filed Critical Univ British Columbia
Publication of NZ563261A publication Critical patent/NZ563261A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
NZ563261A 2001-12-03 2002-12-02 Effectors of innate immunity NZ563261A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33663201P 2001-12-03 2001-12-03
NZ533721A NZ533721A (en) 2001-12-03 2002-12-02 Peptides and their use for treating inflammatory conditions

Publications (1)

Publication Number Publication Date
NZ563261A true NZ563261A (en) 2008-08-29

Family

ID=23316965

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ533721A NZ533721A (en) 2001-12-03 2002-12-02 Peptides and their use for treating inflammatory conditions
NZ563261A NZ563261A (en) 2001-12-03 2002-12-02 Effectors of innate immunity

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ533721A NZ533721A (en) 2001-12-03 2002-12-02 Peptides and their use for treating inflammatory conditions

Country Status (12)

Country Link
EP (1) EP1470249A2 (fr)
JP (1) JP2005536985A (fr)
KR (1) KR20040077669A (fr)
CN (2) CN100357324C (fr)
AU (1) AU2002365675B2 (fr)
CA (1) CA2468907A1 (fr)
HK (1) HK1075677A1 (fr)
IL (1) IL162300A0 (fr)
NZ (2) NZ533721A (fr)
SG (1) SG159382A1 (fr)
WO (1) WO2003048383A2 (fr)
ZA (1) ZA200404919B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7687454B2 (en) 2001-12-03 2010-03-30 The University Of British Columbia Effectors of innate immunity determination
US7507787B2 (en) 2001-12-03 2009-03-24 The University Of British Columbia Effectors of innate immunity
MXPA06002828A (es) * 2003-09-12 2006-06-23 Univ British Columbia Efectores de determinacion de inmunidad innata.
WO2006005190A1 (fr) * 2004-07-14 2006-01-19 Inimex Pharmaceuticals Inc. Procede de criblage destine a la protection contre l'infection microbienne
US7638340B2 (en) 2005-06-22 2009-12-29 Seikagu Corporation Method of eliminating reactivity of lipoarabinomannan and application of the same
GB0517090D0 (en) 2005-08-19 2005-09-28 Tcp Innovations Ltd ApoE mimetic agents
JP2009509552A (ja) * 2005-10-04 2009-03-12 イニメックス ファーマシューティカルズ インコーポレイテッド 先天免疫を調節することによる感染の処置および予防を含む、免疫関連疾患障害の処置および予防のための新規ペプチド
ES2497441T3 (es) 2006-08-21 2014-09-22 The University Of British Columbia Péptidos inmunomoduladores catiónicos pequeños
SG175573A1 (en) * 2006-10-04 2011-11-28 Inimex Pharmaceuticals Inc Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity
WO2009057695A1 (fr) * 2007-10-30 2009-05-07 Olympus Corporation Procédé de détection d'un adénome ou d'un cancer par analyse génétique
WO2010026489A1 (fr) * 2008-09-05 2010-03-11 The University Of British Columbia Modulateurs d'immunité innée
EP2346521A4 (fr) * 2008-10-06 2012-06-20 Univ Colorado Regents Peptides et procédés d'utilisation
JO3623B1 (ar) 2012-05-18 2020-08-27 Amgen Inc البروتينات المرتبطة بمولد المستضاد st2
KR20230119130A (ko) 2020-12-14 2023-08-16 리제너론 파마슈티칼스 인코포레이티드 인히빈 서브유닛 베타 e(inhbe) 억제제로 대사 장애 및 심혈관 질환을 치료하는 방법
WO2023063994A1 (fr) * 2021-10-13 2023-04-20 Phenomune, LLC Méthodes de test pour la détermination du phénotype t2r et leurs applications

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877274A (en) * 1995-06-02 1999-03-02 University Of British Columbia Antimicrobial cationic peptides
DE19734161A1 (de) * 1997-08-07 1999-04-01 Jerini Biotools Gmbh SDF-1 - Antagonisten
US6288212B1 (en) * 1998-08-28 2001-09-11 The University Of British Columbia Anti-endotoxic, antimicrobial cationic peptides and methods of use therefor

Also Published As

Publication number Publication date
CN101215601A (zh) 2008-07-09
CA2468907A1 (fr) 2003-06-12
EP1470249A2 (fr) 2004-10-27
CN1615368A (zh) 2005-05-11
JP2005536985A (ja) 2005-12-08
HK1075677A1 (en) 2005-12-23
CN100357324C (zh) 2007-12-26
WO2003048383A2 (fr) 2003-06-12
AU2002365675A1 (en) 2003-06-17
AU2002365675B2 (en) 2007-04-05
NZ533721A (en) 2007-12-21
SG159382A1 (en) 2010-03-30
WO2003048383A3 (fr) 2004-08-05
ZA200404919B (en) 2006-05-31
IL162300A0 (en) 2005-11-20
KR20040077669A (ko) 2004-09-06

Similar Documents

Publication Publication Date Title
US7507787B2 (en) Effectors of innate immunity
AU2002365675B2 (en) Effectors of innate immunity
US20070134261A1 (en) Effectors of innate immunity
Hirotani et al. Regulation of lipopolysaccharide-inducible genes by MyD88 and Toll/IL-1 domain containing adaptor inducing IFN-β
Hedges et al. γδ T cells respond directly to pathogen-associated molecular patterns
Vaidya et al. Toll-like receptors and innate antiviral responses
US20030148316A1 (en) Methods and compositions relating to plasmacytoid dendritic cells
US6187557B1 (en) c-IAP1 and c-IAP2: inhibitors of apoptosis
da Silva et al. Comparison of gene expression patterns induced by treatment of human umbilical vein endothelial cells with IFN-α 2b vs. IFN-β 1a: understanding the functional relationship between distinct type I interferons that act through a common receptor
US20100048408A1 (en) Method for study, determination or evaluation by gene expression analysis
US7687454B2 (en) Effectors of innate immunity determination
WO1997006182A1 (fr) Inhibiteurs de l'apoptose
CA2466877C (fr) Compositions utiles comme ligands du recepteur de type recepteur 1 des peptides formyles et procedes d'utilisation de celles-ci
US20070190533A1 (en) Effectors of innate immunity
AU2002323255A1 (en) Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof
AU2007201885A1 (en) Effectors of innate immunity
US20060019303A1 (en) Method to identify and analyze genes having modified expression in stimulated T cells
KR20070033314A (ko) 양이온성 펩티드를 사용한 선천 면역의 자극 방법
Nagel et al. Identification of genes differentially expressed in T cells following stimulation with the chemokines CXCL12 and CXCL10
JP2009500314A (ja) 遺伝子調節
WO2020032894A1 (fr) Peptide immunomodulateur dérivé d'une séquence précurseur de terminal amino cxcl8
Natarajan Characterization of chemokine CCL19 in the duck (Anas platyrhynchos)
Conti CLR16. 2: The identification, characterization, and functional analysis of a novel regualtor of T cell activation

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)